Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was $323.00 for the day, down -0.76% from the previous closing price of $325.47. In other words, the price has decreased by -$0.76 from its previous closing price. On the day, 0.5 million shares were traded. MDGL stock price reached its highest trading level at $333.9599 during the session, while it also had its lowest trading level at $322.01.
Ratios:
Our analysis of MDGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.93 and its Current Ratio is at 5.98. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.15.
On June 11, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $382.
On April 22, 2024, BofA Securities started tracking the stock assigning a Underperform rating and target price of $150.BofA Securities initiated its Underperform rating on April 22, 2024, with a $150 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 24 ’25 when Huntsman Carole sold 347 shares for $335.24 per share. The transaction valued at 116,328 led to the insider holds 10,438 shares of the business.
Sibold William John sold 1,584 shares of MDGL for $531,020 on Jan 24 ’25. The President and CEO now owns 54,303 shares after completing the transaction at $335.24 per share. On Jan 24 ’25, another insider, Taub Rebecca, who serves as the Pres., R&D, and CMO of the company, sold 648 shares for $335.24 each. As a result, the insider received 217,236 and left with 456,662 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDGL now has a Market Capitalization of 7044759040 and an Enterprise Value of 6165275648. For the stock, the TTM Price-to-Sale (P/S) ratio is 91.72 while its Price-to-Book (P/B) ratio in mrq is 9.06. Its current Enterprise Value per Revenue stands at 80.263 whereas that against EBITDA is -11.267.
Stock Price History:
The Beta on a monthly basis for MDGL is -0.41, which has changed by 0.72626495 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, MDGL has reached a high of $368.29, while it has fallen to a 52-week low of $168.25. The 50-Day Moving Average of the stock is 2.16%, while the 200-Day Moving Average is calculated to be 21.48%.
Shares Statistics:
MDGL traded an average of 422.27K shares per day over the past three months and 422990 shares per day over the past ten days. A total of 21.81M shares are outstanding, with a floating share count of 18.39M. Insiders hold about 15.68% of the company’s shares, while institutions hold 104.08% stake in the company. Shares short for MDGL as of 1736899200 were 4083736 with a Short Ratio of 9.67, compared to 1734048000 on 4734136. Therefore, it implies a Short% of Shares Outstanding of 4083736 and a Short% of Float of 26.87.
Earnings Estimates
Current recommendations for the stock of the company come from 14.0 analysts. The consensus estimate for the next quarter is -$3.87, with high estimates of -$3.34 and low estimates of -$4.66.
Analysts are recommending an EPS of between -$22.67 and -$25.0 for the fiscal current year, implying an average EPS of -$23.59. EPS for the following year is -$13.57, with 16.0 analysts recommending between -$8.29 and -$26.35.
Revenue Estimates
For the next quarter, 14 analysts are estimating revenue of $103.14M. There is a high estimate of $114.54M for the next quarter, whereas the lowest estimate is $87.4M.
Based on 15 analysts’ estimates, the company’s revenue will be $512.9M in the next fiscal year. The high estimate is $644.6M and the low estimate is $295.51M.